PPAR‐γ Activation Prevents Septic Cardiac Dysfunction via Inhibition of Apoptosis and Necroptosis
Authors:
Open Access
- 1 January 2017
- journal article
- research article
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2017 (1) , 8326749
Abstract
Sepsis‐induced cardiac dysfunction remains one of the major causes of death in intensive care units. Overwhelmed inflammatory response and unrestrained cell death play critical roles in sepsis‐induced cardiac dysfunction. Peroxisome proliferator‐activated receptor‐ (PPAR‐) γ has been proven to be cardioprotective in sepsis. However, the mechanism of PPAR‐γ‐mediated cardioprotection and its relationship with inflammation and cell death are unclear. We hypothesized that activation of PPAR‐γ by reducing cardiac inflammation, myocardial apoptosis, and necroptosis may prevent myocardial dysfunction in sepsis. Rats were subjected to cecal ligation and puncture (CLP) with or without PPAR‐γ agonist (rosiglitazone) or antagonist T0070907 (T007). After CLP, cardiac function was significantly depressed, which was associated with the destructed myocardium, upregulated proinflammatory cytokines, and increased apoptosis, necrosis, and necroptosis. This process is corresponded with decreased inhibitor κB (IκBα) and increased NF‐κB, receptor‐interacting protein kinase‐1 (RIP1), RIP3, and mixed lineage kinase‐like (MLKL) protein. Activation of PPAR‐γ by rosiglitazone pretreatment enhanced PPAR‐γ activity and prevented these changes, thereby improving the survival of septic rats. In contrast, inhibition of PPAR‐γ by T007 further exacerbated the condition, dropping the survival rate to nearly 0%. In conclusion, PPAR‐γ activation by reducing proinflammatory cytokines, apoptosis, and necroptosis in the myocardium prevents septic myocardial dysfunction.Keywords
Funding Information
- Natural Science Foundation of Hunan Province (2017JJ3438)
- National Natural Science Foundation of China (81600251)
This publication has 41 references indexed in Scilit:
- Pioglitazone reduces inflammation through inhibition of NF-κB in polymicrobial sepsisInnate Immunity, 2013
- Peroxisome Proliferator–Activated Receptor-γ Activation Prevents Sepsis-Related Cardiac Dysfunction and Mortality In MiceCirculation: Heart Failure, 2013
- Reduced Peroxisome Proliferator-Activated Receptor α Expression Is Associated With Decreased Survival and Increased Tissue Bacterial Load in SepsisShock, 2012
- Inhibition of c-Jun-N-terminal Kinase Increases Cardiac Peroxisome Proliferator-activated Receptor α Expression and Fatty Acid Oxidation and Prevents Lipopolysaccharide-induced Heart DysfunctionJournal of Biological Chemistry, 2011
- Extracellular Administration of BCL2 Protein Reduces Apoptosis and Improves Survival in a Murine Model of SepsisPLOS ONE, 2011
- NEUTROPHIL PARALYSIS IN SEPSISShock, 2010
- Rosiglitazone Ameliorates Endotoxin-Induced Organ Damage in Conscious RatsBiological Research For Nursing, 2009
- PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-?? IS A NEW THERAPEUTIC TARGET IN SEPSIS AND INFLAMMATIONShock, 2005
- Septic shockThe Lancet, 2005
- Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in SepsisChest, 1992